NEXT Life Sciences Raises $1.55M for Plan A, Its Male Contraceptive
ORIGINALLY POSTED ON FEMTECH INSIDER
NEXT Life Sciences is set to revolutionize contraception with Plan A, a safe, effective, and reversible birth control method for men. Responding to the growing demand for male contraceptives, NEXT aims to initiate clinical trials by the end of 2023.
Plan A utilizes Vasalgel, a proprietary hydrogel acquired by NEXT, to provide a reliable contraceptive solution for men. Instead of permanently cutting the vas deferens, the hydrogel acts as a flexible filter, blocking sperm flow and preventing pregnancy. Preclinical studies have shown rapid restoration of sperm flow after the hydrogel is dissolved and flushed from the vas deferens.
NEXT Life Sciences CEO L.R. Fox shares: “In developing Plan A…